Cardiovascular complications of breast cancer therapy in older adults

Oncologist

Volumn 16, Issue 8, 2011, Pages 1138-1143

  Shenoy, Chetan ^a   Klem, Igor ^a   Crowley, Anna Lisa ^a   Patel, Manesh R ^a   Winchester, Mark A ^a   Owusu, Cynthia ^b   Kimmick, Gretchen G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Breast cancer; Cardiotoxicity; Cardiovascular complications; Elderly; Geriatrics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILIPEMIC AGENT; CARBOPLATIN; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ANEMIA; ARTICLE; BODY MASS; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EXERCISE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPROTEINEMIA; KIDNEY FUNCTION; LIFESTYLE; LIFESTYLE MODIFICATION; POLYPHARMACY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FEMALE; HUMANS; RISK FACTORS;

EID: 80052193537     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0348     Document Type: Article

References (88)

1. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
2. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
3. Smith BD, Smith GL, Hurria A et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009; 27:2758-2765.
4. Bouchardy C, Rapiti E, Blagojevic S et al. Older female cancer patients: Importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858-1869.
5. Owusu C, Lash TL, Silliman RA. Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 2007;102:227-236.
6. Kornblith AB, Kemeny M, Peterson BL et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989-996.
7. Yee KW, Pater JL, Pho L et al. Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 2003;21:1618-1623.
8. Doyle JJ, Neugut AI, Jacobson JS et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005; 23:8597-8605.
9. Kimmick GG, Fleming R, Muss HB et al. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging 1997;10:34-49.
10. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808-3815.
11. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341: 2061-2067.
12. Kimmick GG, Peterson BL, Kornblith AB et al. Improving accrual of older persons to cancer treatment trials: A randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 2005;23:2201-2207.
13. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389.
14. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
15. Ryberg M, Nielsen D, Cortese G et al. New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008;100:1058-1067.
16. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979;91:710-717.
17. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709.
18. Gennari A, Salvadori B, Donati S et al. Cardiotoxicity of epirubicin/ paclitaxel-containing regimens: Role of cardiac risk factors. J Clin Oncol 1999;17:3596-3602.
19. Fumoleau P, Roché H, Kerbrat P et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92.
20. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
21. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
22. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238.
23. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
24. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Semin Oncol 2001;28(suppl 3):20-27.
25. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 2003;42:779-791.
26. Chassany O, Urien S, Claudepierre P et al. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 1996; 38:571-573.
27. Kumar GN, Walle UK, Bhalla KN et al. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993;80:337-344.
28. Wildiers H, Highley MS, de Bruijn EA et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-1242.
29. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983;43:4467-4469.
30. Sandström M, Freijs A, Larsson R et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581-1588.
31. Robert J, Rigal-Huguet F, Huet S et al. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Leukemia 1990;4:227-229.
32. Marchiset-Leca D, Leca FR, Galeani A et al. Pharmacokinetics and metabolism of pirarubicin in humans: Correlation with pharmacodynamics. Cancer Chemother Pharmacol 1995;36:239-243.
33. Aoki S, Tsukada N, Nomoto N et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 1998;17:465-470.
34. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
35. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-285.
36. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncologist 2000;5:224-237.
37. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
38. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-2447.
39. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-4642.
40. Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: Pharmacology and polypharmacy. Curr Treat Options Oncol 2008; 9:191-203.
41. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. The Oncologist 2010;15:507-522.
42. Baker SD, van Schaik RH, Rivory LP et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341-8350.
43. Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 1995;40:523-530.
44. Launay-Vacher V, Gligorov J, Le Tourneau C et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010;124:745-753.
45. Monfardini S. Evaluation of renal function in elderly cancer patients. Ann Oncol 2004;15:183-184.
46. Sweeney C, Blair CK, Anderson KE et al. Risk factors for breast cancer in elderly women. Am J Epidemiol 2004;160:868-875.
47. Dranitsaris G, Rayson D, Vincent M et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;107:443-450.
48. Monsuez JJ, Charniot JC, Vignat N et al. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3-15.
49. Albini A, Pennesi G, Donatelli F et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
50. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: In-cidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-2247.
51. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol 2009;10: 391-399.
52. Jones LW, Haykowsky MJ, Swartz JJ et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-1441.
53. Curigliano G, Mayer EL, Burstein HJ et al. Cardiac toxicity from systemic cancer therapy: A comprehensive review. Prog Cardiovasc Dis 2010;53: 94-104.
54. Cohen HJ.Amodel for the shared care of elderly patients with cancer. JAm Geriatr Soc 2009;57(suppl 2):s300-s302.
55. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. The Oncologist 2008;13:1224-1234.
56. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JAm Coll Cardiol 2010;55:213-220.
57. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International Cardi-Oncology Society. Prog Cardiovasc Dis 2010;53:88-93.
58. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36.
59. Flood KL, Carroll MB, Le CV et al. Polypharmacy in hospitalized older adult cancer patients: Experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 2009; 7:151-158.
60. Millward MJ, Webster LK, Rischin D et al. Phase I trial of cremophor EL with bolus doxorubicin. Clin Cancer Res 1998;4:2321-2329.
61. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007;7: 600-607.
62. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
63. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25: 3859-3865.
64. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070.
65. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
66. Robson D, Verma S. Anthracyclines in early-stage breast cancer: Is it the end of an era? The Oncologist 2009;14:950-958.
67. Brambilla C, Rossi A, Bonfante V et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986;70:261-266.
68. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988;6:679-688.
69. Gasparini G, Dal Fior S, Panizzoni GA et al. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 1991;14:38-44.
70. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988;6:976-982.
71. Jain KK, Casper ES, Geller NL et al.Aprospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-826.
72. Lopez M, Contegiacomo A, Vici P et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989;64:2431-2436.
73. Villani F, Galimberti M, Comazzi R et al. Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 1989;25: 13-18.
74. van Dalen EC, Michiels EM, Caron HN et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;(5):CD005006.
75. Safra T. Cardiac safety of liposomal anthracyclines. The Oncologist 2003; 8(suppl 2):17-24.
76. Weiss AJ, Metter GE, Fletcher WS et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976;60:813-822.
77. Chlebowski RT, Paroly WS, Pugh RP et al. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980;64:47-51.
78. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-139.
79. Torti FM, Bristow MR, Howes AE et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745-749.
80. van Dalen EC, van der Pal HJ, Caron HN et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009;(4):CD005008.
81. van Dalen EC, Michiels EM, Caron HN et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006;(4):CD005006.
82. Hasinoff BB, Herman EH. Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 2007;7:140-144.
83. van Dalen EC, Caron HN, Dickinson HO et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(2):CD003917.
84. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-145.
85. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
86. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
87. Iliskovic N, Singal PK. Lipid lowering: An important factor in preventing adriamycin-induced heart failure. Am J Pathol 1997;150:727-734.
88. Galvão DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005;23:899-909